Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 7, 2021
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics TrialDaniel M F Claassens, Pim W M van Dorst, Gerrit J A Vos, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|September 10, 2023
Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF modelPascal M Burger, Gianluigi Savarese, Jasper Tromp, et al.
Circulation. Cardiovascular Interventions|March 16, 2021
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics SubanalysisDaniel M F Claassens, Thomas O Bergmeijer, Gerrit J A Vos, et al.
European Journal of Heart Failure|March 13, 2026
Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trialPeter van der Meer, Geert H D Voordes, Marlene A T Vijver, et al.
The New England Journal of Medicine|September 4, 2019
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCIDaniel M F Claassens, Gerrit J A Vos, Thomas O Bergmeijer, et al.
European Journal of Heart Failure|August 30, 2024
Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trialDirk J van Veldhuisen, Michiel Rienstra, Arend Mosterd, et al.
The New England Journal of Medicine|March 18, 2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsPaul M Ridker, James Revkin, Pierre Amarenco, et al.
European Journal of Preventive Cardiology|May 19, 2021
Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectivenessSteven H J Hageman, Jannick A N Dorresteijn, Michiel L Bots, et al.
Eclinicalmedicine|October 21, 2024
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trialsAernoud T L Fiolet, Michiel H F Poorthuis, Tjerk S J Opstal, et al.
Pageof 12